rituximab

Ligand id: 6780

Name: rituximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

No information available.
Summary of Clinical Use
Used to treat CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Rituximab is also used to suppress antibody-mediated rejection in living-donor kidney recipients prior to an ABO-incompatible transplant [4-5]. A modified formulation containing rituximab + human hyaluronidase (Rituxan Hycela) that can be delivered subcutaneously (the original rituximab only formulation was administered intravenously) was FDA approved in June 2017 for the treatment of previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Mechanism Of Action and Pharmacodynamic Effects
Anti-CD20 monoclonal antibody. The Fab regions of this antibody bind to the CD20 antigen on B lymphocytes, and the Fc domain recruits antibodies and complements to mediate cell lysis.